Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
NY Valves 25: TRISCEND II Substudy
Author(s): Added: 2 weeks ago
New York Valves 25 - A substudy of TRISCEND II investigating the effect of transcatheter tricuspid valve replacement (TTVR) on preference-weighted health status showed significant benefits in patients who received TTVR.We are joined by Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, US) to discuss the findings from a substudy of the TRISCEND II trial, which aimed to create an… View more

Intervention
Oral P2Y12 Inhibitors and Drug Interactions
Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 1 month ago

Anticoagulation

Prevention & Chronic Conditions
PERFORMANCE II: Two-Year Outcomes
Author(s): William Gray Added: 2 months ago
Safety and effectiveness outcomes of a 3-in-1 carotid stent delivery system show no major strokes at 30-day and one-year follow ups and significantly low rates of clinically driven target lesion revascularisation at two years.Dr William Gray (Main Line Health, Pennsylvania, US) joins us to discuss the first European presentation of the two-year outcomes from PERFORMANCE II (NCT04201132; Contego… View more

Vascular Disease and Surgery
Factor XIa Inhibitors’ Future Position in AF
Author(s): Maki Komiyama , Moritake Iguchi , Hiromichi Wada , et al Added: 1 year ago

Anticoagulation
Timing of SGLT2 Inhibitors in Heart Failure
Author(s): Moritake Iguchi , Hiromichi Wada , Felipe Martínez , et al Added: 2 years ago

Heart Failure

Prevention & Chronic Conditions
TCT 24: The TRISCEND II Trial
Author(s): Susheel Kodali Added: 8 months ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter tricuspid valve replacement (TTVR) compared to optimal medical therapy for patients with severe tricuspid regurgitation (TR).Dr Susheel Kodali (Columbia University Medical Center, New York, US) joins us onsite at TCT Conference to discuss the findings from the TRISCEND II Trial (NCT04482062; Edwards Lifesciences).TRISCEND II is a… View more

Intervention
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 11 months ago

Anticoagulation
EuroPCR 24: The CAGEFREE II Trial
Author(s): Ling Tao Added: 1 year ago
EuroPCR 2024 — Investigator, Dr Ling Tao joins us to discuss the findings from the CAGEFREE II trial.Compared to drug-eluting stents, drug-coated balloons are associated with faster vessel healing and reduced thrombotic burden, therefore patients treated with DCBs require a less intensive antiplatelet therapy. CAGEFREE II investigated the effectiveness and safety of a tailored one-month DAPT… View more

Intervention
ESC 23: The DANPACE II Trial
Author(s): Mads Brix Kronborg Added: 1 year ago
ESC 2023 — Dr Mads Brix Kronborg (Aarhus University Hospital, DE) joins us to discuss the findings from the DANPACE II Trial (NCT00236158). DANPACE II (The DANPACE Investigator Group) trial aimed to compare patients who were randomised in a 1:1 ratio to either a base rate of 60 beats per minute and rate-adaptive DDD (DDDR-60 Group) or a base rate of 40bpm and non-rate adaptive DDD (DDD-40… View more

Electrophysiology & Arrhythmia
ACC 24 Late-Breaker Discussion: The AEGIS-II Trial
Author(s): Harriette Van Spall , Michael C Gibson Added: 1 year ago
ACC 2024 — Late-breaker host, Dr Harriette Van Spall and Principal Investigator, Dr C Michael Gibson discuss the AEGIS-II trial (CSL Behring) (NCT03473223).This phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study investigated the efficacy and safety of an apolipoprotein A-I (apoA-I), CSL112 in patients with acute coronary syndrome (ACS). Investigators enrolled… View more

Prevention & Chronic Conditions

MI/ACS